The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Journal of Hypertension

Volumn 37, Issue 7, 2019, Pages 1334-1343

  Piperidou, Alexia ^a   Sarafidis, Pantelis ^a   Boutou, Afroditi ^b   Thomopoulos, Costas ^c   Loutradis, Charalampos ^a   Alexandrou, Maria Eleni ^d   Tsapas, Apostolos ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Papanikolaou Hospital   (Greece)

^c HELENA VENIZELOU HOSPITAL   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

albuminuria; diabetic kidney disease; proteinuria; SGLT 2 inhibitors

Indexed keywords

ALBUMIN; CREATININE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; CREATININE URINE LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG APPROVAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADMINISTRATION AND DOSAGE; BLOOD PRESSURE; DIABETIC NEPHROPATHY; DRUG EFFECT;

ALBUMINURIA; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85062438203     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000002050     Document Type: Review

References (50)

1. Matthews DR, Tsapas A,. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res 2008; 5: 216-218.
2. Fowler MJ,. Microvascular and macrovascular complications of diabetes. Clin Diab 2011; 29: 116-122.
3. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN,. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010; 55: 835-847.
4. Sarafidis PA, Ruilope LM,. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014; 85: 536-546.
5. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150.
6. Sarafidis PA, Ruilope LM,. Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression. J Renin Angiotensin Aldosterone Syst 2012; 13: 217-219.
7. Abdul-Ghani MA, Norton L, DeFronzo RA,. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012; 12: 230-238.
8. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E,. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274.
9. Imprialos KP, Sarafidis PA, Karagiannis AI,. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens 2015; 33: 2185-2197.
10. Sarafidis PA, Tsapas A,. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016; 374: 1092.
11. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ,. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752-772.
12. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR,. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 2014; 306: F188-F193.
13. Thomas MC,. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014; 5: 53-61.
14. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M,. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334.
15. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N,. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657.
16. Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D,. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 2015; 26: 2055-2064.
17. Higgins J, Green S,. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011].; 2011.
18. Review Manager (RevMan) [computer program]. Version Version 5.3: The Cochrane Collaboration; 2014.
19. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T,. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol 2013; 167: 1443-1449.
20. Hozo SP, Djulbegovic B, Hozo I,. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
21. Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S,. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016; 59: 1860-1870.
22. Kohan DE, Fioretto P, Tang W, List JF,. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-971.
23. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V,. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28: 368-375.
24. Kashiwagi A, Shiga T, Akiyama N, Kazuta K, Utsuno A, Yoshida S, Ueyama E,. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int 2015; 6: 104-116.
25. Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, Ueyama E,. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152-160.
26. Kashiwagi A, Akiyama N, Shiga T, Kazuta K, Utsuno A, Yoshida S, Ueyama E,. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int 2015; 6: 125-138.
27. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L,. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016; 29: 391-400.
28. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ,. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
29. Nomoto H, Miyoshi H, Sugawara H, Ono K, Yanagiya S, Oita M,. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr 2017; 9: 54.
30. Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL,. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes Obes Metab 2017; 19: 1363-1370.
31. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC,. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.
32. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D,. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-1027.
33. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C,. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 610-621.
34. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD,. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18: 590-597.
35. Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A,. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 66-88. e20.
36. Sarafidis PA, Khosla N, Bakris GL,. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49: 12-26.
37. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC,. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369-384.
38. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S,. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
39. Xu L, Li Y, Lang J, Xia P, Zhao X, Wang L,. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ 2017; 5: e3405.
40. Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K,. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes 2018; 12: 265-283.
41. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI,. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94: 26-39.
42. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A,. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014; 9: e100777.
43. O'Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F,. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015; 309: F227-F234.
44. Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ, Choi DE,. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016; 11: e0158810.
45. Brenner BM, Lawler EV, Mackenzie HS,. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777.
46. Norton L, Shannon CE, Fourcaudot M, Hu C, Wang N, Ren W,. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 2017; 19: 1322-1326.
47. Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E,. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19: 1289-1294.
48. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M,. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57: 2599-2602.
49. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A,. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
50. Papadopoulou E, Angeloudi E, Karras S, Sarafidis P,. The optimal blood pressure target in diabetes mellitus: a quest coming to an end? J Hum Hypertens 2018; 32: 641-650.